BeiGene

Founded in 2010, BeiGene is a global biotechnology company that discovers and develops innovative oncology treatments and aims to make their medicines more accessible and affordable to cancer patients worldwide. The company has more than 9,200 colleagues globally and administrative offices on three continents, as well as one of the largest oncology research teams in the world. BeiGene continues to expand its broad in-house internal clinical development capabilities to make its therapies more available for patients around the globe. BeiGene’s innovative BTK inhibitor BRUKINSA® (zanubrutinib) has been approved in more than 65 markets as a treatment for various blood cancers, and the company's other internally developed cornerstone medicine, tislelizumab, is currently under review by regulators in the U.S. and the EU for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. The company’s broad and deep pipeline has the potential to address 80 of cancers by incidence. Adjacent to its product portfolio and pipeline, the company also sponsors programs aimed at serving the broader needs of oncology patients, such as a program to raise awareness of mental health resources for people and families affected by cancer.

Domain

beigene.com

Country

United States

Industry

Biotechnology

Employees

10001+

Last Funding

$2080.0M

Founded

2009